Amgen announced the completion of its acquisition of Ilypsa, a private company developing non-absorbed drugs for renal disorders. The transaction provides Amgen, a biotech firm based in Thousand Oaks, with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on hemodialysis. The acquisition was originally announced June 4.
